chemotherapy and angiogenesis inhibitor

This page covers all chemotherapy and angiogenesis inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting VEGF, DNA synthesis and repair pathways.

Targets

VEGF, DNA synthesis and repair pathways

Phase 2 pipeline (1)

• Folfox plus Bevacizumab · Canadian Cancer Trials Group · Oncology
  FOLFOX plus Bevacizumab inhibits angiogenesis and disrupts tumor blood supply through VEGF inhibition, while FOLFOX induces DNA damage and apoptosis in rapidly dividing cells.

Patent intelligence

• chemotherapy and angiogenesis inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates